Literature DB >> 2758694

The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus.

S Mouritsen1, M Høier-Madsen, A Wiik, O Orum, N Strandberg Pedersen.   

Abstract

In order to elucidate the fine specificity of anti-cardiolipin antibodies (ACA) in patients with SLE compared to patients with syphilis (SY) various inhibition experiments were performed. Seven SLE sera and eight SY sera positive for ACA were diluted and preincubated with either cardiolipin VDRL-antigen, mitochondial particles, dsDNA, ssDNA or dilution buffer. The sera were subsequently assayed for residual ACA activity of IgG or IgM class using a sensitive ELISA technique. Significant inhibition of IgM ACA activity in SLE sera was found with cardiolipin, VDRL-antigen and mitochondrial particles. Cardiolipin inhibited binding to a significantly higher extent than the other antigens. In SY sera significant inhibition of the IgM ACA activity was found with all antigens used. The strongest inhibition was seen using VDRL-antigen. Inhibition of IgG ACA activity could only be clearly estimated in SY sera where VDRL-antigen was found to be a much stronger inhibitor than the rest, purified cardiolipin being the weakest. Only two out of seven SLE sera were IgG ACA positive which made a clear conclusion impossible but a strong inhibitory capability of pure cardiolipin and a weaker inhibition with VDRL-antigen was found. This study disclosed a difference between SLE and SY sera showing strong reactivity of ACA in SLE sera with purified cardiolipin, contrasting to ACA in SY sera which predominantly reacted with cardiolipin in the liposome environment, as found in the VDRL-antigen and in mitochondrial particles.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758694      PMCID: PMC1541844     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders.

Authors:  E N Harris; A E Gharavi; G D Wasley; G R Hughes
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

2.  A DNA antigen that reacts with antisera to cardiolipin.

Authors:  M Guarnieri; D Eisner
Journal:  Biochem Biophys Res Commun       Date:  1974-05-20       Impact factor: 3.575

Review 3.  Sjögren's syndrome. A review with emphasis on immunological features.

Authors:  R Manthorpe; K Frost-Larsen; H Isager; J U Prause
Journal:  Allergy       Date:  1981-04       Impact factor: 13.146

4.  Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients.

Authors:  E Christensen; J Crowe; D Doniach; H Popper; L Ranek; J Rodés; N Tygstrup; R Williams
Journal:  Gastroenterology       Date:  1980-02       Impact factor: 22.682

5.  Antibodies cross-reactive with DNA and cardiolipin in patients with systemic lupus erythematosus.

Authors:  T Koike; H Tomioka; A Kumagai
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids.

Authors:  E M Lafer; J Rauch; C Andrzejewski; D Mudd; B Furie; B Furie; R S Schwartz; B D Stollar
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

8.  Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex.

Authors:  E J Demant; P K Jensen
Journal:  Eur J Biochem       Date:  1983-05-16

9.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

10.  Coronary artery bypass graft failure--an autoimmune phenomenon?

Authors:  K E Morton; T P Gavaghan; S A Krilis; G E Daggard; D W Baron; J B Hickie; C N Chesterman
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

View more
  8 in total

Review 1.  Laboratory techniques in the diagnosis of syphilis: a review.

Authors:  J J van der Sluis
Journal:  Genitourin Med       Date:  1992-12

Review 2.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Differences in functional activity of anticardiolipin antibodies from patients with syphilis and those with antiphospholipid syndrome.

Authors:  S S Pierangeli; G H Goldsmith; S Krnic; E N Harris
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 4.  Recent advances in the diagnosis of antiphospholipid syndrome.

Authors:  Hyun-Sook Chi
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis.

Authors:  S Loizou; C G Mackworth-Young; C Cofiner; M J Walport
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

7.  Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria.

Authors:  P H Jakobsen; S D Morris-Jones; L Hviid; T G Theander; M Høier-Madsen; R A Bayoumi; B M Greenwood
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

8.  High prevalence of autoantibodies among Danish centenarians.

Authors:  K Andersen-Ranberg; M HØier-Madsen; A Wiik; B Jeune; L Hegedus
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.